A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Name: A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Published: 2022
License: Public Domain

HiberCell, Inc. · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

non-small-cell-lung-cancer nsclc

squamous cell carcinoma of head and neck, colo-rectal cancer, non small cell lung cancer, transitional cell carcinoma of the bladder, other solid tumors, clear cell renal cell carcinoma, scchn, crc, nsclc, tcc, phase 1, first in human

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 842721
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.